Expert explaining key treatable traits in COPD: eosinophilic inflammation
Author :Sanofi
Editorial team
Watch Prof. Brian Lipworth share insights on eosinophilic inflammation (5 minutes).
Meet Prof. Brian Lipworth, Head of the Scottish Centre for Respiratory Research at Ninewells Hospital and Medical School, University of Dundee. As an international expert in respiratory medicine, he explains how recognizing treatable traits can help clinicians choose the right biologic therapy to improve outcomes for patients with COPD.
Prof. Brian Lipworth explaining key treatable traits: eosinophilic inflammation
Did you know that 30–40% of COPD patients have type 2 inflammation? In this video, Prof. Brian Lipworth explains how identifying eosinophilic inflammation can support clinicians in understanding when eosinophil measurements may be useful in patient assessment. Learn why repeated and historical eosinophil measurements are important for accurate patient identification.
Relaterade Artiklar
Webcast: Targeting COPD with type 2 inflammation - emerging biologic landscape
Explore the Latest Insights in COPD Management and Biologic Therapies.
In this COPD Research Forum, leading healthcare professionals discuss critical topics such as IL-33, lung function trajectories, and mucus plugging in COPD.
Den här webbplatsen innhåller information som endast är riktad till sjukvårdspersonal. Vänligen bekräfta nedan för att ta del av information, filmer, podcast och övrigt material.
